Effect of a Cardiac Rehabilitation Program on Chronic Heart Failure Patients in Yaoundé, Cameroon

Yaounde Central Hospital30 enrolled

Overview

CARECA-CHF study is a non-randomized, prospective, single-arm study, enrolled ambulatory patients with stable chronic heart failure \[New York Heart Association (NYHA) class II/III\]. Patients will be followed-up during a period of 06-08 weeks. The aim of this study is to assess the effect of a cardiac rehabilitation program on patients with stable chronic heart failure in Yaoundé, Cameroon.

CARECA-CHF study is a non-randomized, prospective, single-arm study, multicentric study. Patients with stable chronic heart failure \[New York Heart Association (NYHA) class II/III\] will be enrolled ambulatory. The program will take place during a period of 06-08 weeks. The aim of this study is to assess the effect of a cardiac rehabilitation program on patients with stable chronic heart failure in a resource-limited country.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Chronic Heart Failure (CHF)

Interventions

CHF PatientsOTHER

Cardiac rehabilitation program on CHF patients on 06-08 weeks. Program will include: physical aerobic re-training, therapeutic education on CHF, psychological follow-up, nutritional education

Eligibility

Sex: ALLMin age: 21 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with stable chronic heart failure confirmed by a cardiac ultrasound and whose severity is rated stage II or III of NYHA followed at Yaoundé central hospital and Yaoundé general hospital; * Stable under treatment; * Whose cardiac ultrasound is less than six months old; * Having given his free and informed consent. Exclusion Criteria: * Poor adherence to the cardiac rehabilitation program activities; * Patients lost insight the program; * Withdrawal of informed consent.

Locations (1)

Dr Chris Nadège Nganou-Gnindjio

Yaoundé, Cameroon

Outcomes

Primary Outcomes

Change of VO2 max

Variation of VO2 max at baseline and the end of the study

Time frame: 8 weeks

Secondary Outcomes

Variation in 6-minute walk test (6MWT) distance

Variation in 6MWT in meter distance from the baseline to week 6 or 8. By using pedometer

Time frame: 8 weeks

Variation of duration of exercise and maximum load

variation in duration of exercise and maximum load expressed by watt power

Time frame: 8 weeks

Variation in level of anxiety and depression;

Difference in level of anxiety and depression assessed by a questionnaire

Time frame: 8 weeks

Change in quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLWHFQ)

Change in quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLWHFQ) Minnesota Living With Heart Failure Questionnaire score at Week 8 adjusted for baseline

Time frame: 8 weeks

Variation of time-domain heart rate variability (HRV) parameters

Variation of time-domain heart rate variability parameters before and after the intervention

Time frame: 8 weeks

Variation of frequency-domain HRV parameters

variation of frequency-domain HRV parameters before and after the intervention. Variation of frequency-domain HRV parameters (HF, LF, LF/HF) before and after the intervention.

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.